1. Home
  2. CBLL vs SPRY Comparison

CBLL vs SPRY Comparison

Compare CBLL & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CeriBell Inc.

CBLL

CeriBell Inc.

HOLD

Current Price

$18.25

Market Cap

750.1M

Sector

N/A

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$8.58

Market Cap

788.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBLL
SPRY
Founded
2014
2015
Country
United States
United States
Employees
280
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
750.1M
788.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CBLL
SPRY
Price
$18.25
$8.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
1
Target Price
$23.20
$40.00
AVG Volume (30 Days)
319.7K
1.6M
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$84,278,000.00
Revenue This Year
$29.57
$87.40
Revenue Next Year
$28.44
$81.64
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.85
$6.66
52 Week High
$24.33
$18.63

Technical Indicators

Market Signals
Indicator
CBLL
SPRY
Relative Strength Index (RSI) 47.80 50.04
Support Level $17.17 $7.82
Resistance Level $19.67 $8.61
Average True Range (ATR) 0.78 0.59
MACD 0.05 0.06
Stochastic Oscillator 65.86 51.45

Price Performance

Historical Comparison
CBLL
SPRY

About CBLL CeriBell Inc.

CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: